Compugen (CGEN) Q1 2025 earnings summary

Executive summary

• Leadership transition announced for September 2025: CEO moves to Executive Chair, CSO becomes CEO, and Chair of the Board steps down.

• Initiated a platform trial of COM701 maintenance therapy in platinum-sensitive ovarian cancer in Q2 2025.

• Continued advancement of early-stage and clinical immuno-oncology pipeline, with focus on COM701 and strategic collaborations.

• AstraZeneca expanded rilvegostomig program to ten Phase 3 trials across multiple cancer types; early data to be presented at ASCO 2025.

• Ongoing recruitment for Phase 1 trial of GS-0321 (anti-IL18BP antibody) licensed to Gilead.

Financial highlights

• Cash, cash equivalents, short-term deposits, and marketable securities totaled $103.7 million as of March 31, 2025.

• Q1 2025 revenue was $2.3 million, down from $2.6 million in Q1 2024, mainly from Gilead license agreement milestone recognition.

• R&D expenses were $5.8 million in Q1 2025, down from $6.4 million in Q1 2024; G&A expenses remained flat at $2.4 million.

• Net loss for Q1 2025 was $7.2 million ($0.08 per share), nearly unchanged from $7.3 million ($0.08 per share) in Q1 2024.

• No debt as of March 31, 2025.

Outlook and guidance

• Cash runway expected to fund operations into 2027, excluding additional cash inflows.

• Interim analysis from COM701 ovarian cancer sub-trials expected in H2 2026.

• Anticipated milestone and royalty revenues from AstraZeneca's rilvegostomig program if successful.

• Continued investment in early-stage pipeline and support for ongoing clinical trials.